Vaccines for preventing smallpox

Cochrane Database of Systematic Reviews

Volumn , Issue 3, 2007, Pages

  Metzger, Wolfram ^a   Mordmueller, B G ^b  

^a MAX PLANCK INSTITUTE FOR INFECTION BIOLOGY   (Germany)

^b NONE

Author keywords

*Bioterrorism; Humans; Smallpox vaccine adverse effects; immunology; *therapeutic use ; Smallpox immunology; *prevention control

Indexed keywords

INACTIVATED VACCINE; JAPANESE ENCEPHALITIS VACCINE; LIVE VACCINE; PLACEBO;

CHINA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; EPIDEMIC ENCEPHALITIS; FEVER; HEADACHE; HUMAN; IMMUNOGENICITY; INJECTION SITE ERYTHEMA; INJECTION SITE PAIN; INJECTION SITE SWELLING; META ANALYSIS; MYALGIA; NAUSEA; RANDOMIZED CONTROLLED TRIAL; REVIEW; SEIZURE; SYSTEMATIC REVIEW; VIRUS NEUTRALIZATION; VIRUS STRAIN;

EID: 44949206551     PISSN: 1469493X     EISSN: None     Source Type: Journal    
DOI: 10.1002/14651858.CD004913.pub2     Document Type: Review

References (126)

1. Artenstein 2005 {published data only} *Artenstein AW, Johnson C, Marbury TC, Morrison D, Blum PS, Kemp T, et al.A novel cell culture-derived smallpox vaccine in vaccinia-naive adults. Vaccine 2005;23(25):3301-9.
2. Frey 2002a {published data only} Belshe RB, Newman FK, Frey SE, Couch RB, Treanor JJ, Tacket CO, et al.Dose-dependent neutralizing-antibody responses to vaccinia. Journal of Infectious Diseases 2004;189(3):493-7.
3. *Frey SE, Couch RB, Tacket CO, Treanor JJ, Wolff M, Newman FK, et al.National Institute of Allergy and Infectious Diseases Smallpox Vaccine Study Group. Clinical responses to undiluted and diluted smallpox vaccine. New England Journal of Medicine 2002;346(17):1265-74.
4. Frey 2002b {published data only} *Frey SE, Newman FK, Cruz J, Shelton WB, Tennant JM, Polach T, et al.Dose-related effects of smallpox vaccine. New England Journal of Medicine 2002;346(17): 1275-80.
5. Frey 2003 {published data only} *Frey SE, Newman FK, Yan L, Belshe RB. Response to smallpox vaccine in persons immunized in the distant past. JAMA 2003;289(24):3294-9.
6. Greenberg 2005 {published data only} *Greenberg RN, Kennedy JS, Clanton DJ, Plummer EA, Hague L, Cruz J, et al.Safety and immunogenicity of new cell-cultured smallpox vaccine compared with calf-lymph derived vaccine: a blind, single-centre, randomised controlled trial. Lancet 2005;365(9457):398-409.
7. Hsieh 2006 {published data only} *Hsieh SM, Chen SY, Sheu GC, Hung MN, Chou WH, Chang SC, et al.Clinical and immunological responses to undiluted and diluted smallpox vaccine with vaccinia virus of Lister strain. Vaccine 2006;24(4):510-5.
8. Kim 2005 {published data only} *Kim SH, Yeo SG, Jang HC, Park WB, Lee CS, Lee KD, et al.Clinical responses to smallpox vaccine in vaccinia-naive adults and previously vaccinated populations: undiluted and diluted Lancy-Vaxina vaccine in a single-blind, randomized prospective trial. Journal of Infectious Diseases 2005;192(6):1066-70.
9. Rock 2004 {published data only} *Rock MT, Yoder SM, Talbot TR, Edwards KM, Crowe Jr. JE. Adverse events after smallpox immunizations are associated with alterations in systemic cytokine levels. Journal of Infectious Diseases 2004;189(8):1401-10.
10. Talbot 2004 {published data only} *Talbot RT, Stapleton JT, Brady RC, Winokur PL, Bernstein DI, Germanson T, et al.Vaccination success rate and reaction profile with diluted and undiluted smallpox vaccine. JAMA 2004;292(10):1205-12.
11. Talbot TR, Bredenberg HK, Smith M, LaFleur BJ, Boyd A, Edwards KM. Focal and generalized folliculitis following smallpox vaccination among vaccinia-naive recipients. JAMA 2003;289(24):3290-4.
12. Weltzin 2003 {published data only} *Weltzin R, Liu J, Pugachev KV, Myers GA, Coughlin B, Blum PS, et al.Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nature Medicine 2003;9(9):1125-30.
13. Agafonov 1977 Agafonov VI, Vorob'ev AA, Gapochko KG, Marennikova SS, Patrikeev GT. Comparative assessment of the means and methods of immunizing humans against smallpox. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii 1977;6:31-5.
14. Andzhaparidze 1980 Andzhaparidze OG, Unanov SS, Chernos VI, Strelkov VV, Antonova TP. Moscow Research Institute of Viral Preparations tissue-culture smallpox vaccine in a coded control experiments of adult revaccination by scarification. Voprosy Virusologii 1980;4:443-6.
15. Banerji 1972 Banerji SC, Sharma KL, Srivastava BC, Gupta RD. A comparative study of smallpox vaccination techniques under field conditions. Indian Journal of Medical Research 1972;60(5):772-7.
16. Benenson 1977 Benenson AS, Cherry JD, McIntosh K, Connor JD, Alling DW, Nakano J, et al.Clinical and serologic study of four smallpox vaccines comparing variations of dose and route of administration. Basic study and laboratory standardization. Journal of Infectious Diseases 1977;135(1):135-44.
17. Chernos 1977 *Chernos VI, Unanov SS, Antonova TP, Nemtsov IM, Andzhaparidze OG. Study of the properties of a tissue smallpox vaccine manufactured by the Moscow Research Institute of Viral Preparations. Voprosy Virusologii 1977;1:71-6.
18. Chernos 1990 Chernos VI, Cheliapov NV, Antonova TP, Rakhilina LE, Unanov SS, Al'tshtein AD, et al.Verification of the safety, inoculability, reactogenicity and antigenic properties of a live recombinant smallpox-hepatitis B vaccine in an experiment in volunteers. Voprosy Virusologii 1990;35(2):132-5.
19. Cherry 1977 Cherry JD, McIntosh K, Connor JD, Benenson AS, Alling DW, Rolfe UT, et al.Clinical and serologic study of four smallpox vaccines comparing variations of dose and route of administration. Primary percutaneous vaccination. Journal of Infectious Diseases 1977;135(1):145-54.
20. Christensen 1966 Christensen H, Kjolbye E, Aung Tun U. Effect of simultaneous BCG and smallpox vaccination in schoolchildren. Report of a WHO-sponsored preliminary study. Bulletin of the World Health Organization 1966;35(4):633-40.
21. Denisov 1975 Denisov GM, Kossova ET, Rybalko DI. Immunological efficacy of smallpox vaccination in children with relative contraindications to vaccination. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii 1975;1:68-72.
22. Evgrafov 1978 Evgrafov VA, Kossova ET, Piskareva NA, Leonov VM, Khliabich GN. Study of the multiple puncture method in smallpox vaccination of children. Zhurnal Mikrobiologii, Epidemiologii, i Imunobiologii 1978;1:51-3.
23. Galasso 1977 Galasso GJ, Mattheis MJ, Cherry JD, Connor JD, McIntosh K, Benenson AS. Clinical and serologic study of four smallpox vaccines comparing variations of dose and route of administration. Summary. Journal of Infectious Diseases 1977;135(1):183-6.
24. Gateff 1973 Gateff C, Relyveld EH, Le Gonidec G, Vincent J, Labusquiere R, McBean M, et al.Study of a new pentavalent vaccine combination. Annales de Microbiologie 1973;124(3):387-409.
25. Herrero 1969 Herrero E, von Mutzenbecher H. Smallpox vaccine from cell cultures. Clinical trials and comparison with dermovaccine. Zentralblatt Fur Bakteriologie, Parasitenkunde, Infektionskrankheiten Und Hygiene - 1 - Abt - Medizinisch-Hygienische Bakteriologie, Virusforschung Und Parasitologie - Originale 1969;209(4):415-22.
26. Huerta 2006 Huerta M, Balicer RD, Mimouni D, Goldberg A, Furman MM, Klement E, et al.Validity of self-assessment of skin reaction after smallpox vaccination. Public Health Reports 2006;121(1):45-50.
27. Karchmer 1971 Karchmer AW, Friedman JP, Casey HL, Shope TC, Riker JB, Kappelman MM, et al.Simultaneous administration of live virus vaccines. Measles, mumps, poliomyelitis, and smallpox. American Journal of Diseases of Children 1971;121(5):382-8.
28. Kennedy 2004 Kennedy JS, Frey SE, Yan L, Rothman AL, Cruz J, Newman FK, et al.Induction of human T cell-mediated immune responses after primary and secondary smallpox vaccination. Journal of Infectious Diseases 2004;190(7):1286-94.
29. Khliabich 1978 Khliabich GN, Sumarokov AA, Ozeretskovskii NA, Karinskaia GA, Gurvich EB. Comparative study of smallpox vaccines from strains B-51, EM-63 and L-IVP in a controlled epidemiologic trial. I. Reactogenic characteristics of the smallpox vaccines. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii 1978;8:20-6.
30. Lelong 1952 Lelong M, Ramon J. Smallpox vaccination trials using a formalin vaccine. Presse Médicale 1952;60(13):265-6.
31. Lev 1972 Lev MI, Sergeichik II, Kulikov IA. Comparative evaluation of the needleless, syringe and scarification methods of vaccination. Voenno-Meditsinskii Zhurnal 1972;9:955-7.
32. Lin 1965 Lin HT. A study of the effect of simultaneous vaccination with BCG and smallpox vaccine in newborn infants. Bulletin of the World Health Organization 1965;33(3):321-36.
33. Marennikova 1966 Marennikova SS, Tashpulatov GM. Comparative study of the inoculability, reactogenicity and antigenic activity of smallpox vaccines prepared from various strains (preliminary report). Voprosy Virusologii 1966;11(3):266-72.
34. Marennikova 1977 Marennikova SS, Matsevich GR, Sokolova AF, Shul'ga LG, Manenkova GM. Immunological characteristics of the 2-stage method of smallpox vaccination. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii 1977;5:105-9.
35. Martin du Pan 1966 Martin du Pan R. Should one vaccinate against smallpox by scarification or multipuncture? Comparative study of 2 smallpox vaccines administered in 2 different ways. Pédiatrie 1966;21(3):299-309.
36. Mel'nikov 2005 Mel'nikov SA, Podkuiko VN, Khamitov RA, Maksimov VA, Markov VI, Vorob'ev AA, et al.Clinical studies of vaccine TEOVac under the conditions of remote revaccination. Zhurnal Mikrobiologii, Epidemiologii, i Immunobiologii 2005;6:29-33.
37. Meyer 1964 Meyer HM, Hostetler DD, Bernheim BC, Rogers NG, Lambin P, Chassary A, et al.Response of volta children to jet inoculation of combined live measles, smallpox and yellow fever vaccines. Bulletin of the World Health Organization 1964;30:783-94.
38. Mihailescu 1988 Mihailescu R, Velea V, Chirescu N, Topciu V, Doroiu N. Immunogenic capacity of a fractionated lyophilized smallpox vaccine. Revista de Igiena, Bacteriologie, Virusologie, Parazitologie, Epidemiologie, Pneumoftiziologie 1988;33(1):35-9.
39. Millar 1969 Millar JD, Roberto RR, Wulff H, Wenner HA, Henderson DA. Smallpox vaccination by intradermal jet injection. I. Introduction, background and results of pilot studies. Bulletin of the World Health Organization 1969;41(6):749-60.
40. Mobest 1974 Mobest H. Analysis of the immunogenic effect of liquid and freeze-dried smallpox vaccine (as demonstrated inmore than 20,000 persons vaccinated three times). Zentralblatt für Bakteriologie, Parasitenkunde, Infektionskrankheiten und Hygiene. Erste Abteilung Originale. Reihe A: Medizinische Mikrobiologie und Parasitologie 1974;227(1-4):263-81.
41. Murruzzu 1967 Murruzzu I. Comparison of the 3 types of smallpox vaccines. (Ist. Sier. Milanese, Ist. Sier. Sclavo and Ist Sier. Berna). Giornale di Batteriologia, Virologia ed Immunologia 1967;60(1):17- 21.
42. Nath 1970 Nath LM, Rao YS, Rao TM. A comparative study of the rotary lancet and bifurcate needle techniques of smallpox vaccination. Indian Journal of Medical Research 1970;58(3):388-93.
43. Neff 1969 Neff JM, Millar JD, Roberto RR, Wulff H. Smallpox vaccination by intradermal jet injection. 3. Evaluation in a well vaccinated population. Bulletin of the World Health Organization 1969;41(6):771-8.
44. Nyerges 1968 Nyerges G, Hollos I, Losonczy G. Efficiency of smallpox revaccination repeated at three-year intervals. II. Comparative study of the international reference strain (Elstree) and the Hungarian vaccine strain (Budapest). Acta Microbiologica Academiae Scientiarum Hungaricae 1968;15(3):187-97.
45. Nyerges 1972 Nyerges G, Csukas M. Immunogenicity of smallpox vaccines prepared from strains of different reactogenicity. Acta Microbiologica Academiae Scientiarum Hungaricae 1972;19(2):103-9.
46. Nyerges 1973 Nyerges G, Erdos L, Melly F. Smallpox vaccination immunity in relation to number of insertions. Bulletin of the World Health Organization 1973;48(4):397-400.
47. Pattanayak 1970 Pattanayak S, Arora DD, Sehgal CL, Raghavan NG, Topa PK, Subrahmanyam YK. Comparative studies of smallpox vaccination by the bifurcated needle and rotary lancet techniques. Bulletin of the World Health Organization 1970;42(2):305-10.
48. Petersen 1966 Petersen ES Norby G. A comparison between two techniques of smallpox vaccination. Danish Medical Bulletin 1966;13(6):168-9.
49. Podkuiko 1993 Podkuiko VN, Vorob'ev AA, Krasnianskii VP, Patrikeev GT, Mikhailov VV, Dorokhina TV, et al.Peroral immunization - a method for enhancing the safety of the recombinant vector (the vaccinia virus). Vestnik Rossiiskoi Akademii Meditsinskikh Nauk/Rossiiskaia Akademiia Meditsinskikh Nauk 1993;2:39-44.
50. Roberto 1969 Roberto RR, Wulff H, Millar JD. Smallpox vaccination by intradermal jet injection. 2. Cutaneous and serological responses to primary vaccination in children. Bulletin of the World Health Organization 1969;41(6):761-9.
51. Sergeev 2004 Sergeev AA, Sergeev AN, Petrishchenko VA, Shishkina LN, Kochneva GV, Zhukov VA, et al.Reactogenicity, safety and immunogenicity of a recombinant bivaccine against smallpox and hepatitis B in limited clinical trials. Voprosy Virusologii 2004;49(5):22-6.
52. Sherman 1967 Sherman PM, Hendrickse RG, Montefiore D, Peradze T, Coker G. Simultaneous administration of live measles virus vaccine and smallpox vaccine. British Medical Journal 1967;2(553):672-6.
53. Shinozaki 1969 Shinozaki T. Study of postvaccinal changes in blood antibodies. 4. Comparison of inoculation reactions using classic, standard and low toxic strains. Nippon Shonika Gakkai Zasshi. Acta Paediatrica Japonica 1969;73(4):497-504.
54. Snell 1965 Snell PH. A comparison of two methods of vaccination against smallpox in Nigeria. West African Medical Journal 1965;14(6):233-5.
55. Tauraso 1972 Tauraso NM, Myers MG, Nau EV, O'Brien TC, Spindel SS, Trimmer RW. Effect of interval between inoculation of live smallpox and yellow-fever vaccines on antigenicity inman. Journal of Infectious Diseases 1972;126(4):362-71.
56. Unanov 1966 Unanov SS, Marennikova SS, Akatova EM, Gurvich EB, Kantsova TI, Mal'tseva NN, et al. Comparative evaluation of smallpox vaccines. Voprosy Virusologii 1966;11(5):519-25.
57. Vaughan 1972 Vaughan JP, Lindqvist K, Brooke D, Doyle RF. Combined BCG and smallpox immunization: a preliminary report on a method using the W.H.O. bifurcated needle. East African Medical Journal 1972;49(3):207-12.
58. Vaughan 1973 Vaughan JP, Menu JP, Lindqvist KJ, Vennema A. A trial with a mixed BCG/smallpox vaccine given intradermally. Journal of Tropical Medicine and Hygiene 1973;76(10):262-4.
59. Vollmar 2006 Vollmar J, Arndtz N, Eckl KM, Thomsen T, Petzold B, Mateo L, et al.Safety and immunogenicity of IMVAMUNE, a promising candidate as a third generation smallpox vaccine. Vaccine 2006;24(12):2065-70.
60. Waibel 2004 Waibel KH, Ager EP, Topolski RL, Walsh DS. Randomized trial comparing vaccinia on the external surfaces of 3 conventional bandages applied to smallpox vaccination sites in primary vaccinees. Clinical Infectious Diseases 2004;39(7):1004-7.
61. Waibel 2006 Waibel KH, Golding H, Manischewitz J, King LR, Tuchscherer M, Topolski RL, et al.Clinical and immunological comparison of smallpox vaccine administered to the outer versus the inner upper arms of vaccinia-naive adults. Clinical Infectious Diseases 2006;42(4): e16-20.
62. Wesley 1975 Wesley RB, Speers WC, Neff JM, Ruben FL, Lourie B. Evaluation of two kinds of smallpox vaccine: CVI-78 and calf lymph vaccine. I. Clinical and serologic response to primary vaccination. Pediatric Research 1975;9(8):624-8.
63. Acambis-a *Acambis. Effect of dose on safety, tolerability, and immunogenicity of ACAM2000 smallpox vaccine in adults with previous smallpox vaccination. www.clinicaltrials.gov NCT00053482 (accessed 23 February 2007).
64. Acambis-b Acambis. Effect of dose on safety, tolerability, and immunogenicity of ACAM2000 smallpox vaccine in adults without previous smallpox vaccination. www.clinicaltrials.gov NCT00053495 (accessed 23 February 2007).
65. Acambis-c Acambis. Dose safety, tolerability, and immunogenicity of ACAM1000 smallpox vaccine in adults without previous smallpox vaccination. www.clinicaltrials.gov NCT00053508 (accessed 23 February 2007).
66. Acambis-d *Acambis. Safety, tolerability, and immune response of ACAM3000 Modified Vaccinia Ankara (MVA) smallpox vaccine in adults. www.clinicaltrials.gov NCT00079820 (accessed 23 February 2007).
67. Acambis-e *Acambis. Safety study of MVA smallpox vaccine in HIV-positive subjects who are vaccinia naive. www.clinicaltrials.gov NCT00282581 (accessed 23 February 2007).
68. Acambis-f *Acambis. Safety study of MVA smallpox vaccine in subjects with a history of atopic dermatitis (AD). www.clinicaltrials.gov NCT003389103 (accessed 23 February 2007).
69. Bavarian Nordic-a Bavarian Nordic. Safety, tolerability and immune response of IMVAMUNE (MVA-BN) smallpox vaccine in HIV infected patients. www.clinicaltrials.gov NCT00189904 (accessed 23 February 2007).
70. Bavarian Nordic-b Bavarian Nordic. Safety, tolerability and immune response of IMVAMUNE (MVA-BN®) smallpox vaccine in patients with atopic disorders. www.clinicaltrials.gov NCT00189917 (accessed 23 February 2007).
71. Bavarian Nordic-c Bavarian Nordic. Study on safety, tolerability and immunogenicity of an MVA-BN vaccine administered to healthy subjects. www.clinicaltrials.gov NCT00189943 (accessed 23 February 2007).
72. Bavarian Nordic-d Bavarian Nordic. Dose-finding study to evaluate the immunogenicity of three different dose levels of the IMVAMUNE (MVA-BN) smallpox vaccine. www.clinicaltrials.gov NCT00189956 (accessed 23 February 2007).
73. Bavarian Nordic-e Bavarian Nordic. Take rate, immunogenicity and safety of Elstree-BN smallpox vaccine in healthy vaccinia-naive subjects. www.clinicaltrials.gov NCT00189969 (accessed 23 February 2007).
74. Bavarian Nordic-f *Bavarian Nordic. A randomized, double-blind, placebo-controlled study on immunogenicity and safety of MVA-BN® (IMVAMUNE™) smallpox vaccine in healthy subjects. www.clinicaltrials.gov NCT00316524 (accessed 23 February 2007).
75. Bavarian Nordic-g Bavarian Nordic. Safety and immunogenicity of MVA-BN® (IMVAMUNE) smallpox vaccine in HIV infected patients. www.clinicaltrials.gov NCT00316589 (accessed 23 February 2007).
76. Bavarian Nordic-h *Bavarian Nordic. A Phase II study on immunogenicity and safety of MVA-BN® (IMVAMUNE™) smallpox vaccine in subjects with atopic dermatitis. www.clinicaltrials.gov NCT00316602 (accessed 23 February 2007).
77. Bristol-Myers Squibb Bristol-Myers Squibb. A comparative Phase I clinical study of HIVAC-1e and smallpox (vaccinia) vaccines in previously (vaccinia) vaccinated and unvaccinated volunteers. www.clinicaltrials.gov NCT00002261 (accessed 23 February 2007).
78. DynPort DynPort Vaccine Company. Study of reactogenicity, safety, immunogenicity, and pock lesion formation of a cell-cultured smallpox vaccine compared to Dryvax®. www.clinicaltrials.gov NCT00042094 (accessed 23 February 2007).
79. NIAID-a National Institute of Allergy and Infectious Diseases. A multicenter, randomized, placebo-controlled, double-blind trial to evaluate the safety and immunogenicity of a recombinant vaccinia-HIV-1 IIIB Env/Gag/Pol Vaccine (TBC-3B). www.clinicaltrials.gov NCT00000767 (accessed 23 February 2007).
80. NIAID-b National Institute of Allergy and Infectious Diseases. Dryvax dilution - prev vacc adults (dose response study of Dryvax vaccine against smallpox in previously vaccinated adults). www.clinicaltrials.gov NCT00032708 (accessed 23 February 2007).
81. NIAID-c National Institute of Allergy and Infectious Diseases. Vaccinia virus vaccine (APSV) in vaccinia-naive subjects: PILOT (Safety and preliminary efficacy of various concentrations of Aventis Pasteur's smallpox vaccine, USP (APSV) in vaccinia-naive adults). www.clinicaltrials.gov NCT00038987 (accessed 23 February 2007).
82. NIAID-d National Institute of Allergy and Infectious Diseases. Dryvax seropositives #2 (Expanded Trial) (dose-response study of Dryvax vaccine against smallpox in previously vaccinated adults). www.clinicaltrials.gov NCT00050505 (accessed 23 February 2007).
83. NIAID-e National Institute of Allergy and Infectious Diseases. APSV in vaccinia-naive adults. www.clinicaltrials.gov NCT00050518 (accessed 23 February 2007).
84. NIAID-g National Institute of Allergy and Infectious Diseases. Dressing preparations for smallpox (A comparison of dressing preparations for smallpox vaccination sites with a focus upon the risk of secondary transmission of vaccinia virus). www.clinicaltrials.gov NCT00063856 (accessed 23 February 2007).
85. NIAID-h National Institute of Allergy and Infectious Diseases. Human immune responses smallpox (evaluation of human immune response to smallpox vaccine (vaccinia virus). www.clinicaltrials.gov NCT00068198 (accessed 23 February 2007).
86. NIAID-i *National Institute of Allergy and Infectious Diseases. Combination study with MVA BN and Dryvax (safety and immunogenicity of MVA-BN in a dose response regimen followed by administration of Dryvax). www.clinicaltrials.gov NCT00082446 (accessed 23 February 2007).
87. NIAID-j *National Institute of Allergy and Infectious Diseases. ACAM 3000 MVA at Harvard Medical School (Acambis Modified Vaccinia Ankara) immunization followed by Dryvax vaccination of healthy vaccinia-naïve adults). www.clinicaltrials.gov NCT00133575 (accessed 23 February 2007).
88. NIAID-k *National Institute of Allergy and Infectious Diseases. Phase II dose finding study of Acambis MVA smallpox vaccine. www.clinicaltrials.gov NCT00170651 (accessed 23 February 2007).
89. NIAID-l National Institute of Allergy and Infectious Diseases. MVA post-event: dosage level and boost study (evaluation of IMVAMUNE® smallpox vaccine with respect to safety and optimization of immune responses by administration timing, dose level administered, and subsequent boost with Dryvax® smallpox vaccine in vaccinia naive adults). www.clinicaltrials.gov NCT00437021 (accessed 23 February 2007).
90. NIAID-m National Institute of Allergy and Infectious Diseases. Phase I trial of smallpox vaccine (A Phase I/II clinical trial of Modified Vaccinia Virus Ankara (MVA) to evaluate its safety, dosing schedule, immunogenicity and protective efficacy against Dryvax challenge in vaccinia-naive individuals). www.clinicaltrials.gov NCT00046397 (accessed 23 February 2007).
91. NIAID-n National Institutes of Health Clinical Center. Phase I/II trial of modified vaccinia virus Ankara (MVA) vaccine against smallpox. www.clinicaltrials.gov NCT00053742 (accessed 23 February 2007).
92. NIAID-o National Institutes of Health Clinical Center. Immune responses to smallpox vaccination. www.clinicaltrials.gov NCT00325975 (accessed 23 February 2007).
93. Sanofi-Aventis *Sanofi-Aventis. Evaluation of take and safety of a smallpox vaccine in healthy young adults. www.clinicaltrials.gov NCT00258947 (accessed 23 February 2007).
94. Seoul NU *Seoul National University Hospital. Safety and imunogenicity of CJ-50300. www.clinicaltrials.gov NCT00336635 (accessed 23 February 2007).
95. VaxGen *VaxGen. Safety and immunogenicity of LC16m8, a modified vaccinia vaccine, in healthy, previously unvaccinated volunteers. www.clinicaltrials.gov NCT00103584 (accessed 23 February 2007).
96. Aragon 2003 Aragón TJ, Ulrich S, Fernyak S, Rutherford GW. Risks of serious complications and death from smallpox vaccination: A systematic review of the United States experience, 1963-1968. BMC Public Health 2003;3:26.
97. Arness 2004 Arness MK, Eckart RE, Love SS, Atwood JE, Wells TS, Engler RJ, et al.Myocarditis following smallpox vaccination. American Journal of Epidemiology 2004;160(7):642-51.
98. Bicknell 2002 Bicknell WJ. The case for voluntary smallpox vaccination. New England Journal of Medicine 2002;346(17):1323-5. [MEDLINE: 17].
99. Brighton 2004 Brighton Collaboration. Definitions & guidelines. brightoncollaboration. org/en/index/aefi.html (accessed 6 April 2004).
100. CDC 2006 Centers for Disease Control and Prevention. Smallpox fact sheet. www.bt.cdc.gov/agent/smallpox/vaccination/facts.asp 21 February 2006 (accessed 11 January 2007).
101. Drexler 2003 Drexler I, Staib C, Kastenmuller W, Stevanovic S, Schmidt B, Lemonnier FA, et al.Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proceedings of the National Academy of Sciences of the United States of America 2003;100(1):217-22. [MEDLINE: 22].
102. Fenner 1988 Fenner F, Henderson DA, Arita I, Jezek Z, Ladnyi ID. Smallpox and its eradication. Geneva: World Health Organization, 1988.
103. Frey 2002c Frey SE, Couch RB, Tacket CO, Treanor JJ, Wolff M, Newman FK, et al.National Institute of Allergy and Infectious Diseases Smallpox Vaccine Study Group. Clinical responses to undiluted and diluted smallpox vaccine. New England Journal of Medicine 2002;346(17):1265-74.
104. Grabenstein 2003 Grabenstein JD, Winkenwerder W Jr. US military smallpox vaccination program experience. JAMA 2003;289(24):3278- 82.
105. Henderson 1999a Henderson DA. Smallpox: clinical and epidemiologic features. Emerging Infectious Diseases 1999;5(4):537-9.
106. Henderson 1999b Henderson DA, Inglesby TV, Bartlett JG, Ascher MS, Eitzen E, Jahrling PB, et al.Smallpox as a biological weapon:medical and public health management. Working Group on Civilian Biodefense. JAMA 1999;281(22):2127-37. [MEDLINE: 13].
107. Henderson 2001 Henderson DA, Fenner F. Recent events and observations pertaining to smallpox virus destruction in 2002. Clinical Infectious Diseases 2001;33(7):1057-9. [MEDLINE: 14].
108. Higgins 2006 Higgins JPT, Green S, editors. Highly sensitive search strategies for identifying reports of randomized controlled trials in MEDLINE. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6 [updated September 2006]; Appendix 5b. www.cochrane.org/resources/ handbook/hbook.htm (accessed 1 December 2006).
109. Hopkins 1988 Hopkins JW. The eradication of smallpox: organizational learning and innovation in international health administration. Journal of Developing Areas 1988;22(3):321-32. [MEDLINE: 16].
110. HRSA 2006 Health Resources and Services Adminstration. Smallpox Vaccine Injury Compensation Program: Administrative implementation. Federal Register 2006;71(100):29805-11.
111. Juni 2001 Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. BMJ 2001;323(7303):42-6.
112. Kenner 2006 Kenner J, Cameron F, Empig C, Jobes DV, Gurwith M. LC16m8: an attenuated smallpox vaccine. Vaccine 2006;24(47-48): 7009-22.
113. Kretschmar 2006 Kretschmmar M, Walling J, Teunis P, Xing S, Mikolajczyk R. Frequency of adverse events after vaccination with different vaccinia strains. PLoS Medicine 2006;3(8):e272.
114. Lane 1970a Lane JM, Ruben FL, Neff JM, Millar JD. Complications of smallpox vaccination, 1968: results of ten statewide surveys. Journal of Infectious Diseases 1970a;122(4):303-9. [MEDLINE: 20].
115. Lane 1970b Lane JM, Ruben FL, Abrutyn E, Millar JD. Deaths attributable to smallpox vaccination, 1959 to 1966, and 1968. JAMA 1970b;212(3):441-4.
116. Lane 2003 Lane MJ, Goldstein J. Evaluation of 21st-century risks of smallpox vaccination and policy options. Annals of Internal Medicine 2003;138(6):488-93.
117. MMWR 2003 Centers for Disease Control and Prevention. Smallpox vaccine adverse events monitoring and response system for the first stage of the smallpox vaccination program. MMWR 2003;52(5):88-9, 99. [MEDLINE: 18].
118. MMWR 2006 Casey C, Vellozzi C, Mootrey GT, Chapman LE, McCauly M, Roper MH, et al.Vaccinia Case Definition Development Working Group, Advisory Committee on Immunization Practices-Armed Forces Epidemiological Board Smallpox Vaccine Safety Working Group. Surveillance guidelines for smallpox vaccine (vaccinia) adverse reactions. MMWR 2006;55(RR-1):1-16.
119. Neff 2002 Neff JM, Lane JM, Fulginiti VA, Henderson DA. Contact vaccinia - transmission of vaccinia from smallpox vaccination. JAMA 2002;288(15):1901-5. [MEDLINE: 10].
120. Poland 2005a Poland GA, Grabenstein JD, Neff M. The US smallpox vaccination program: a review of a large modern era smallpox vaccination implementation program. Vaccine 2005;23(17-18):2078-81.
121. Poland 2005b Poland GA. Smallpox vaccines: from first to second to third generation. Lancet 2005;365(9457):362-3.
122. Prentice 1989 Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Statistics in Medicine 1989;8(4):431-40.
123. Review Manager 4.2 The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). 4.2 for Windows. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2003.
124. Sejvar 2005 Sejvar J, Boneva R, Lane JM, Iskander J. Severe headaches following smallpox vaccination. Headache 2005;45(1):87- 8.
125. WHO 1980 WHO. Declaration of global eradication of smallpox. Weekly Epidemiological Record 1980;55:145-52.
126. Wiser 2007 Wiser I, Balicer RD, Cohen D. An update on smallpox vaccine candidates and their role in bioterrorism related vaccination strategies. Vaccine 2007;25(6):976-84.